Fulcrum’s Losmapimod Improves Multiple Measures, But Not Primary Endpoint

Secondary Endpoints May Matter More In FSHD Study

The ReDUX4 study missed its biomarker-driven primary endpoint, making it unclear if an additional trial will be needed for regulatory submission.

MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope
Fulcrum presented data from the Phase IIb study of losmapimod in FSHD • Source: Shutterstock

Fulcrum Therapeutics Inc. is arguing that although losmapimod failed to meet the primary endpoint in the Phase IIb ReDUX4 study in facioscapulohumeral muscular dystrophy (FSHD), it met other endpoints measuring clinical benefit that are more important. Whether it can convince the US Food and Drug Administration or will need to conduct another trial could set an important standard for other companies with DUX4-targeting drugs for FSHD currently in preclinical development.

The ReDUX4 results were presented 24 June at the FSHD International Research Congress, showing what Cambridge, MA-based Fulcrum said were clinically relevant and statistically significant benefits compared with placebo on multiple measures of structural and functional disease progression and patient-reported outcomes at 48 weeks

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

More from Scrip

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.